Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Registre international des stents inverseurs de flux (IRF) (IRF)

17 septembre 2026 mis à jour par: Montefiore Medical Center

Résultats des déviateurs de flux pour le traitement des anévrismes intracrâniens - Registre international des stents à déviateur de flux (IRF)

This multicenter retrospective cohort study aims to evaluate and compare the technical performance, safety, and clinical outcomes of intracranial aneurysms treated with flow diverter stents and endosaccular flow disruptors.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Description détaillée

Flow diverters and endosaccular flow disruptors used for the treatment of intracranial aneurysms exhibit distinct procedural and clinical outcomes, with potential differences in device-specific parameters such as procedure time, radiation exposure, adjunct device requirements, and long-term angiographic success. Since the completion of the Pipeline Embolization Device (PED) for the Intracranial Treatment of Aneurysms trial, the field of flow diversion has undergone continuous evolution with the development and approval of several devices. While these devices share a similar mechanism for aneurysm occlusion, their design and delivery systems can vary significantly. Various studies have demonstrated a promising safety and efficacy profile; however, the available data for a direct comparison of the technical and clinical outcomes between these devices remains limited.

The following collaborator is also involved in the research:

Name: Muhammed Amir Essibayi Email: m.amir.essibayi@gmail.com

Type d'étude

Observationnel

Inscription (Estimé)

5000

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Ontario
      • Toronto, Ontario, Canada, M5B 1W8
      • Toronto, Ontario, Canada, M5T 2S8
        • Recrutement
        • Toronto Western Hospital
        • Contact:
        • Chercheur principal:
          • Pascal Mosimann, MD, PD
    • Florida
      • Coral Gables, Florida, États-Unis, 33146
        • Recrutement
        • University of Miami
        • Contact:
        • Chercheur principal:
          • Robert M Starke, MD, MS
      • Jacksonville, Florida, États-Unis, 32224
        • Complété
        • Mayo Clinic Florida
      • Sarasota, Florida, États-Unis, 34239
        • Complété
        • Sarasota Memorial Research Institute
    • Massachusetts
      • Burlington, Massachusetts, États-Unis, 01805
        • Recrutement
        • Lahey Hospital and Medical Center
        • Contact:
        • Chercheur principal:
          • Timo Krings, MD, PhD, MSc
    • Michigan
      • Traverse City, Michigan, États-Unis, 49684
        • Recrutement
        • Munson Medical Center
        • Contact:
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55404
    • New Jersey
      • New Brunswick, New Jersey, États-Unis, 08901
        • Recrutement
        • Robert Wood Johnson University
        • Chercheur principal:
          • Gaurav Gupta, MD
        • Contact:
    • New York
      • Buffalo, New York, États-Unis, 14068
        • Complété
        • University at Buffalo
      • The Bronx, New York, États-Unis, 10467
        • Recrutement
        • Montefiore Medical Center Department of Neurosurgery
        • Chercheur principal:
          • David Altschul, MD
        • Contact:
        • Contact:
    • Pennsylvania
      • Danville, Pennsylvania, États-Unis, 17822
        • Complété
        • Geisinger Health
    • Texas
      • Kingwood, Texas, États-Unis, 77339
        • Complété
        • HCA Houston Healthcare Kingwood

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Patients with intracranial aneurysms who underwent endovascular treatment with flow diverter stents or endosaccular flow disruptors

La description

Inclusion Criteria:

  • Consecutive adult patients (18 years of age or older)

  • Underwent endovascular treatment with one of the following devices:

    a. Endoluminal Flow Diverter Stents: i. Pipeline Flex (Covidien, California, USA) ii. Pipeline Flex with Shield Technology (Covidien) iii. Surpass Streamline (Stryker Neurovascular, California, USA) iv. Surpass Evolve (Stryker) v. Silk flow diverter (Balt Extrusion, Montmorency, France) vi. Flow-Redirection Intraluminal Device (FRED; MicroVention) vii. Flow-Redirection Intraluminal Device X (FRED X; MicroVention) viii. p64 Flow Modulation Device (phenox GmbH) ix. Endovascular clip system (eCLIPs) (eCLIPsTM, eVasc Neurovascular, Vancouver, BC, Canada)

    b. Intrasaccular Flow Disruptors: i. Woven EndoBridge (WEB; MicroVention) ii. Luna/Artisse System (Medtronic) iii. Medina Embolic Device (Medtronic) iv. Contour Neurovascular System (Cerus Endovascular) v. Neqstent Coil Assisted Flow Diverter (Cerus Endovascular) vi. pCONus and pCANvas (phenox GmbH) vii. Nexus Aneurysm Embolization System (EndoStream Medical) viii. CITADEL™ Embolization Device (Balt, USA)

  • Complete medical records and follow-up data available

Exclusion Criteria:

  • Incomplete procedural or follow-up records
  • Non-flow-diverter or non-flow-disruptor treatments (e.g., coiling-only cases)
  • Aneurysms treated with investigational devices not listed within Inclusion Criteria

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: RETROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Endoluminal Flow Diverter Stent

Adults with intracranial aneurysms treated with an endoluminal flow diverter stent as part of routine care.

Intrasaccular Flow Disruptor

Adults with intracranial aneurysms treated with an intrasaccular flow disruptor as part of routine care.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Technical Success
Délai: Periprocedurally, up to 24 hours

Technical Success will be determined by successful deployment of the flow diverter stent or endosaccular flow disruptors. A dichotomous determination (i.e., Yes/No) will be made and summarized for this study.

Periprocedurally, up to 24 hours
Procedural Complications following placement
Délai: From the time of the procedure up to 1 month post treatment

Procedural complications will be identified as the number of instances of the following adverse clinical events: In-stent Thrombosis/Stenosis; Ischemic complications (Transient Ischemic Attack/Stroke), Intracerebral hemorrhage, Aneurysm rupture, and Vessel occlusion due to flow diverter stent or endosaccular flow disruptor placement.

From the time of the procedure up to 1 month post treatment
Clinical Outcomes at Discharge
Délai: Upon study discharge, up to 4 weeks

Clinical outcomes at discharge will be assessed using the modified Rankin Scale (mRS) for neurologic disability. The mRS is a 6-point disability scale with possible scores ranging from 0-5. mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Higher scores are generally associated with less favorable outcomes. For this study patients with an mRS score of 0-2 will be determined to have had a "favorable" outcome to the procedure and patients with an mRS score of 3-5 will have been determined to have had an "unfavorable" outcome.

Upon study discharge, up to 4 weeks
Clinical Outcomes at last available Follow-up
Délai: Up to 24 months post procedure

Clinical outcomes at last available follow-up will be assessed using a variant of the modified Rankin Scale (mRS) for neurologic disability. The classic mRS is a 6-point disability scale with possible scores ranging from 0-5. mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Higher scores are generally associated with less favorable outcomes. For this study patients with an mRS score of 0-2 will be determined to have had a "favorable" outcome to the procedure and patients with an mRS score of 3-5 will have been determined to have had an "unfavorable" outcome. Scoring will also include a 6 to identify patients who have expired.

Up to 24 months post procedure
Immediate Angiographic Outcomes at Discharge - O'Kelly-Marotta (OKM) grading scale
Délai: Upon study discharge, up to 4 weeks

Immediate Angiographic Outcomes at Discharge will be evaluated using the OKM grading scale. The OKM scale will be used to assess the degree of angiographic filling and in the setting of intracranial aneurysms which were treated by endovascular flow diversion. It is used to predict aneurysm closure over time. Patient outcomes will be stratified based on the following scale scores: Grade A: Total filling (>95% of aneurysm remained); Grade B: Subtotal filling (5-95% of aneurysm remained); Grade C: Entry remnant (<5% aneurysm remained); and Grade D: No filling (0% aneurysm remained). As such, the less aneurysm remnant the more favorable the angiographic outcome. The number/percentage of cases of each OKM Grade will be summarized.

Upon study discharge, up to 4 weeks
Immediate Angiographic Outcomes at Discharge - Modified Raymond-Roy Classification (mRRC)
Délai: Upon study discharge, up to 4 weeks

Immediate Angiographic Outcomes at Discharge will also be evaluated using mRRC categorization. mRRC categorization will be used to assess the degree of occlusion achieved when treating an intracranial aneurysm. It categorizes the level of residual contrast filling within an aneurysm after coiling. For purposes of this analysis, Class I will signify complete occlusion; Class II will signify Residual neck occlusion; Class IIIa will signify Residual aneurysm with contrast stasis; and Class IIIb will signify Residual aneurysm without contrast stasis. As such, it is an indicator of how effectively the aneurysm has been sealed off during treatment. The number/percentage of cases of each mRRC category will be summarized.

Upon study discharge, up to 4 weeks
Immediate Angiographic Outcomes at Discharge - WEB Occlusion Scale (WOS)
Délai: Upon study discharge, up to 4 weeks

Immediate Angiographic Outcomes at Discharge will be evaluated using the WOS grading scale. The WOS is a standardized angiographic assessment scale for reporting aneurysm occlusion achieved with endosaccular flow disruptors and can be employed to assess the adequacy of treatment. For purposes of this analysis, WOS Grade A will signify complete occlusion; WOS Grade B will signify Residual neck occlusion; and WOS Grade C will signify Residual aneurysm filling. The number/percentage of cases of each WOS grade category will be summarized.

Upon study discharge, up to 4 weeks
Angiographic Outcomes at last available Follow-up - O'Kelly-Marotta (OKM) grading scale
Délai: Up to 24 months post procedure

Immediate Angiographic Outcomes at Discharge will be evaluated using the OKM grading scale. The OKM scale will be used to assess the degree of angiographic filling and in the setting of intracranial aneurysms which were treated by endovascular flow diversion. It is used to predict aneurysm closure over time. Patient outcomes will be stratified based on the following scale scores: Grade A: Total filling (>95% of aneurysm remained); Grade B: Subtotal filling (5-95% of aneurysm remained); Grade C: Entry remnant (<5% aneurysm remained); and Grade D: No filling (0% aneurysm remained). As such, the less aneurysm remnant the more favorable the angiographic outcome. The number/percentage of cases of each OKM Grade will be summarized.

Up to 24 months post procedure
Angiographic Outcomes at last available Follow-up - Modified Raymond-Roy Classification (mRRC)
Délai: Up to 24 months post procedure

Immediate Angiographic Outcomes at Discharge will also be evaluated using mRRC categorization. mRRC categorization will be used to assess the degree of occlusion achieved when treating an intracranial aneurysm. It categorizes the level of residual contrast filling within an aneurysm after coiling. For purposes of this analysis, Class I will signify complete occlusion; Class II will signify Residual neck occlusion; Class IIIa will signify Residual aneurysm with contrast stasis; and Class IIIb will signify Residual aneurysm without contrast stasis. As such, it is an indicator of how effectively the aneurysm has been sealed off during treatment. The number/percentage of cases of each mRRC category will be summarized.

Up to 24 months post procedure
Angiographic Outcomes at last available Follow-up - WEB Occlusion Scale (WOS)
Délai: Up to 24 months post procedure

Immediate Angiographic Outcomes at Discharge will be evaluated using the WOS grading scale. The WOS is a standardized angiographic assessment scale for reporting aneurysm occlusion achieved with endosaccular flow disruptors and can be employed to assess the adequacy of treatment. For purposes of this analysis, WOS Grade A will signify complete occlusion; WOS Grade B will signify Residual neck occlusion; and WOS Grade C will signify Residual aneurysm filling. The number/percentage of cases of each WOS grade category will be summarized.

Up to 24 months post procedure

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Radiation Exposure
Délai: Periprocedurally, up to 4 hours

Radiation exposure over the course of the procedure will be extracted and summarized. Radiation exposure will be evaluated based on relevant imaging system metrics used to calculate the total radiation dose delivered to the patient based on the fluoroscopy time and the area of the X-ray field exposed during the procedure. Flow diverter stents and endosaccular flow disruptors typically result in significantly lower radiation exposure compared to other endovascular techniques for treating brain aneurysms due to a reduction in fluoroscopy time and overall reduced radiation dose due to the streamlined nature of the procedures.

Periprocedurally, up to 4 hours
Procedure Duration
Délai: Periprocedurally, up to 4 hours

The duration of procedure placement will be extracted and summarized. The duration of the procedure is influenced by the complexity of the aneurysm, the patient's anatomy, and the experience of the interventional radiologist and care team. Shorter procedure duration times are associated with more favorable outcomes.

Periprocedurally, up to 4 hours
Use of Adjunct Devices
Délai: Periprocedurally, up to 4 hours

The use of adjunctive devices such as coils, stents or balloons to further enhance aneurysm occlusion of the flow diverter stent or to facilitate positioning and deployment of the endosaccular flow disruptor within the aneurysm sac during the procedure will be extracted and summarized. The number of adjunct devices will be extracted and summarized.

Periprocedurally, up to 4 hours
Recurrence of Aneurysm
Délai: 6 to 24 months post procedure

The percentage of patients who experienced aneurysm recurrence will be extracted and summarized based on a binary (Yes/No) determination following retrospective record review. The span of time from initial treatment to recurrence will be assessed and summarized.

6 to 24 months post procedure
Aneurysm Retreatment
Délai: 6 to 24 months post procedure

The percentage of patients who required retreatment for a recurrence of aneurysm will be extracted and summarized based on a binary (Yes/No) determination following retrospective record review. The span of time from initial treatment to retreatment will be assessed and summarized.

6 to 24 months post procedure

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 octobre 2023

Achèvement primaire (Estimé)

1 juillet 2027

Achèvement de l'étude (Estimé)

1 juillet 2027

Dates d'inscription aux études

Première soumission

5 décembre 2023

Première soumission répondant aux critères de contrôle qualité

13 décembre 2023

Première publication (Réel)

18 décembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

21 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner